PEN - Penumbra, Inc.
149.56 +0.56 (0.37%)
After hours: 4:26PM EST
| Previous Close | 151.23 |
| Open | 151.14 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 148.78 - 151.47 |
| 52 Week Range | 98.35 - 167.35 |
| Volume | 450,814 |
| Avg. Volume | 295,025 |
| Market Cap | 5.141B |
| Beta (3Y Monthly) | 1.01 |
| PE Ratio (TTM) | 593.63 |
| EPS (TTM) | 0.25 |
| Earnings Date | Feb 26, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 160.14 |
- Zacks•yesterday
Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose
The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.
- Zacks•2 days ago
Align Technology Unveils iTero Element 5D Imaging System
Align Technology (ALGN) continues to expand work flow options of iTero scanners.
- Zacks•5 days ago
Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
- Zacks•6 days ago
NHNKY vs. PEN: Which Stock Is the Better Value Option?
NHNKY vs. PEN: Which Stock Is the Better Value Option?
- Zacks•7 days ago
Here's Why Investors Should Buy CONMED (CNMD) Stock Now
CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.
- Zacks•7 days ago
Boston Scientific Benefits From New Buyouts & Product Launch
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
- Zacks•7 days ago
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
- Zacks•8 days ago
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.
- Zacks•9 days ago
Cardinal Health Strong on Pharmaceutical, Competition Rife
Cardinal Health (CAH) is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019.
- Zacks•12 days ago
Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance
Ecolab (ECL) plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020.
- Markit•12 days ago
See what the IHS Markit Score report has to say about Penumbra Inc.
Penumbra Inc NYSE:PENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for PEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PEN totaled $4.44 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•13 days ago
BD Gains From Solid Global Base, Headwinds Anticipated
Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.
- Zacks•13 days ago
HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors
HealthEquity's (HQY) solid guidance for fiscal 2019 favors stock.
- Simply Wall St.•19 days ago
Penumbra, Inc. (NYSE:PEN) Might Not Be A Great Investment
Want to help shape the future of investing tools? Participate in a short research study and receive a 6-month subscription to the award winning Simply Wall St research tool (valued Read More...
- PR Newswire•21 days ago
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for February 26, 2019
ALAMEDA, Calif. , Jan. 30, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2018 after ...
- Zacks•29 days ago
Varian Medical's (VAR) ProBeam Compact Picked by Biopolis
The development is likely to boost Varian Medical's (VAR) Proton business that declined 12% year over year in the last reported quarter.
- PR Newswire•last month
Penumbra, Inc. Appoints Janet Leeds and Surbhi Sarna to its Board of Directors
ALAMEDA, Calif., Jan. 18, 2019 /PRNewswire/ -- Penumbra, Inc. (PEN) today announced that two new Board members were appointed to its Board of Directors (the "Board") on January 17, 2019. Ms. Janet Leeds was appointed to the Board as a Class I director, effective immediately, and Ms. Surbhi Sarna was appointed to the Board as a Class II director, effective July 1, 2019. "We are thrilled to welcome Janet and Surbhi to our Board. Both of these individuals will bring added experience, perspective, and capability to our Board of Directors which will be invaluable as we continue to grow and scale our company.
- Zacks•last month
Here's Why Investors Should Hold AngioDynamics (ANGO) Now
AngioDynamics' (ANGO) flagship NanoKnife System is currently witnessing robust demand.
- Zacks•last month
Here's Why You Should Invest in OPKO Health (OPK) Right Now
OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.
- Zacks•last month
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.
- GlobeNewswire•last month
Report: Exploring Fundamental Drivers Behind Akamai Technologies, Dynex Capital, MedEquities Realty Trust, HFF, Penumbra, and athenahealth — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Jan. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•last month
Masimo's (MASI) Preliminary Results for 2018 Cheer Investors
Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.
